[HTML][HTML] 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

DY Xie, ZG Ren, J Zhou, J Fan… - Hepatobiliary surgery and …, 2020 - ncbi.nlm.nih.gov
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates
and insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open …

S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee… - The Lancet, 2023 - thelancet.com
Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …

Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment

D Papaconstantinou, DI Tsilimigras… - Journal of hepatocellular …, 2022 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths
worldwide with the incidence of recurrence being as high as 88% even among patients who …

Development of a model including MRI features for predicting advanced-stage recurrence of hepatocellular carcinoma after liver resection

H Jiang, C Yang, Y Chen, Y Wang, Y Wu, W Chen… - Radiology, 2023 - pubs.rsna.org
Background Identifying patients at high risk for advanced-stage hepatocellular carcinoma
(HCC) recurrence after liver resection may improve patient survival. Purpose To develop a …

Tumor microenvironment-triggered MoS2@ GA-Fe nanoreactor: a self-rolling enhanced chemodynamic therapy and hydrogen sulfide treatment for hepatocellular …

H Zheng, B Ma, Y Shi, Q Dai, D Li, E Ren, J Zhu… - Chemical Engineering …, 2021 - Elsevier
We report the preparation of gallic acid (GA)-modified MoS 2 nanosheets (MoS 2@ GA) with
high Fe (III) loading. The MoS 2@ GA-Fe can function as a “Fenton Nanoreactor” in the …

Synergistic impact of alpha-fetoprotein and tumor burden on long-term outcomes following curative-intent resection of hepatocellular carcinoma

DI Tsilimigras, JM Hyer, A Diaz, F Bagante, F Ratti… - Cancers, 2021 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) tumor burden score (TBS) and α-
fetoprotein (AFP) have been considered important predictors of outcomes among patients …

Using hepatocellular carcinoma tumor burden score to stratify prognosis after liver transplantation

D Moris, BI Shaw, L McElroy, AS Barbas - Cancers, 2020 - mdpi.com
Simple Summary Liver transplantation (LT) is an important therapeutic option in selected
patients with hepatocellular carcinoma (HCC). Tumor factors such as size and number of …

Tumor necrosis impacts prognosis of patients undergoing curative-intent hepatocellular carcinoma

T Wei, XF Zhang, F Bagante, F Ratti… - Annals of surgical …, 2021 - Springer
Background The impact of tumor necrosis relative to prognosis among patients undergoing
curative-intent resection for hepatocellular carcinoma (HCC) remains ill-defined. Methods …

Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma

SK Lee, SW Lee, JW Jang, SH Bae, JY Choi… - International Journal of …, 2021 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortalities
worldwide. Patients with early-stage HCC are eligible for curative treatments, such as …

Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma

Z Moazzam, HA Lima, L Alaimo, Y Endo, CF Shaikh… - Surgery, 2022 - Elsevier
Background The ability to predict the incidence, timing, and site of recurrence can be
beneficial to select surgical candidates and inform appropriate postoperative surveillance …